Impact of Endogenous E2 on SSI and GH Rebound
Completed · Phase 1 · Has a placebo group
Conditions studied: Normal Healthy Volunteers
In brief
Endogenous estrogens maintain growth hormone (GH) secretion in postmenopausal women by potentiating endogenous GH-releasing hormone (GHRH) drive and restraining somatostatin inhibition of GH release.
Key facts
- Study ID
- NCT02026973
- Run by
- Mayo Clinic
- People needed
- 62
- Starts
- 2014-03-01
- Expected to finish
- 2015-11-01
- Last updated by the study team
- 2016-03-16
Who can join
Age: 55 and older, up to 80. Sex: female. Healthy volunteers: accepted.
Where it is running
- Mayo Clinic in Rochester — Rochester, Minnesota, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.